Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

Inclusion Criteria: * Age 6 years to 18 years； * Urinary protein excretion \> 200 mg in a 24-hr urine collection； * Without any immunosuppressant medications such as corticosteroids, CNIs and so on； * Estimated GFR ≥ 60 ml/min/1.73m2（estimated with Schwartz formula）； * No history of diabetes； * On stable doses of ACE inhibitors or angiotensin receptor blockers (ARBs) for \> 1 month； * Willing to sign informed consent. Exclusion Criteria: * Autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, or ANCA-associated vasculitis; * Blood pressure less than 5th percentile of the same gender, age, and height; * Uncontrolled urinary tract infection at screening; * At risk for dehydration or volume depletion; * Evidence of hepatic disease: an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) two times the upper limit of normal * History of organ transplantation, cancer, liver disease; * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: 1. History of active inflammatory bowel disease within the last six months; 2. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; 3. Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months; 4. Pancreatic injury or pancreatitis within the last six months; * Participation in another therapeutic trial with an investigational drug within 30 days prior to informed consent; * History of noncompliance to medical regimens or unwillingness to comply with the study protocol.